Encapsulated Papillary Carcinoma of the Breast: Understanding Your Pathology Report

by Jason Wasserman MD PhD FRCPC
April 7, 2026

Encapsulated papillary carcinoma is a rare and distinct type of breast cancer that is usually non-invasive. Non-invasive means the cancer cells have not spread beyond their original location into the surrounding breast tissue. The tumor grows inside a small, cyst-like space and is surrounded by a thick fibrous capsule — a layer of connective tissue that acts as a wall, keeping the cells contained. Inside this space, the cancer cells form branching, finger-like projections called papillae, which is why the tumor is called “papillary.”

Encapsulated papillary carcinoma behaves similarly to ductal carcinoma in situ (DCIS) and is associated with an excellent prognosis, particularly when the capsule is intact and no invasion is present. It is one of the most favorable breast cancer diagnoses on a pathology report.

This article will help you understand the findings in your pathology report. If you had a breast biopsy, you may also find our guide to understanding your breast biopsy report helpful.

What causes encapsulated papillary carcinoma?

The exact cause is not known. Like most breast cancers, encapsulated papillary carcinoma develops after genetic changes (mutations) occur in breast duct cells that cause them to grow and divide abnormally. Most cases occur sporadically — meaning they are not inherited and are not caused by anything the patient did or did not do. The same general risk factors that apply to other breast cancers also apply here, including age, hormonal factors, family history, and inherited gene variants such as BRCA1 or BRCA2.

What are the symptoms?

Many people with encapsulated papillary carcinoma have no symptoms, and the tumor is often found incidentally on a screening mammogram. When symptoms do occur, they can include a breast lump that can be felt or seen on imaging, and nipple discharge, which may occasionally be bloody. Because the tumor grows within a cyst-like space, it sometimes presents as a well-defined, rounded mass that can mimic a benign cyst on imaging.

How is the diagnosis made?

The diagnosis is made after a biopsy or surgical excision of breast tissue is examined under a microscope by a pathologist. A core needle biopsy is usually the first step and often gives enough tissue to confirm the diagnosis. If the entire tumor is then surgically removed, the full pathology report will include additional details such as tumor size, margin status, and the presence or absence of invasion.

Immunohistochemistry — special staining tests that detect specific proteins in the tumor cells — plays an important role in confirming the diagnosis and distinguishing encapsulated papillary carcinoma from benign papillary tumors of the breast. The most important stain used for this purpose tests for myoepithelial cells, described further below.

What does encapsulated papillary carcinoma look like under the microscope?

Under the microscope, encapsulated papillary carcinoma has several characteristic features that pathologists use to make and confirm the diagnosis:

• Papillary structures with fibrovascular cores — The cancer cells arrange themselves around central stalks of connective tissue and small blood vessels called fibrovascular cores, forming branching finger-like projections (papillary structures) that project into the cyst-like space.
• Tumor cell appearance — The cancer cells typically have a relatively uniform appearance, with round-to-oval nuclei. They form a continuous lining over the fibrovascular cores.
• Fibrous capsule — A surrounding layer of thick fibrous tissue (the capsule) encloses the entire tumor, separating it from the adjacent normal breast tissue.
• Absence of myoepithelial cells — Myoepithelial cells are specialized cells that normally form a thin supporting layer around the milk ducts. In normal breast ducts and in benign papillomas, these cells are present along the duct wall and around the papillary structures. In encapsulated papillary carcinoma, myoepithelial cells are absent from within the tumor, both along the fibrovascular cores and at the inner surface of the capsule. This absence is one of the key features that distinguishes encapsulated papillary carcinoma from a benign papilloma, and it is why immunohistochemistry is often performed to make the diagnosis definitively.

Your report may also note that areas of ductal carcinoma in situ (DCIS) are present in the breast tissue surrounding the encapsulated tumor. This is a common finding and does not change the generally favorable prognosis of the encapsulated component, but it may influence decisions about surgical margins and radiation therapy.

Nuclear grade

Pathologists assign a nuclear grade to encapsulated papillary carcinoma based on how abnormal the tumor cell nuclei look and how many cells are actively dividing. Dividing cells are identified as mitotic figures under the microscope.

• Low nuclear grade (grade 1) — Tumor cells have small, uniform nuclei with very few mitotic figures. Associated with the most favorable prognosis.
• Intermediate nuclear grade (grade 2) — Nuclei are larger and slightly irregular, with occasional mitotic figures.
• High nuclear grade (grade 3) — Nuclei look very abnormal, and mitotic figures are frequent. High-grade tumors carry a higher risk of recurrence and are more likely to be associated with invasion or an aggressive invasive component when present.

Invasion

Encapsulated papillary carcinoma with invasion means that tumor cells have broken through the fibrous capsule and grown into the surrounding breast tissue. When this occurs, the tumor behaves more like invasive ductal carcinoma and requires more comprehensive evaluation and treatment. The pathology report will specify whether invasion is present or absent, and, if present, will describe its type (most commonly invasive ductal carcinoma), size, and grade.

Invasion changes the staging from pTis to pT1 or higher (based on the size of the invasive component) and means that lymph node assessment, biomarker testing, and potentially systemic treatment become relevant, as they do for conventional invasive ductal carcinoma.

Tumor size

For non-invasive encapsulated papillary carcinoma, tumor size does not affect staging (all non-invasive EPC is pTis). Still, it is reported because larger tumors may be harder to remove completely and because the overall size informs surgical planning.

When an invasive component is present, the size of the invasive component — not the overall encapsulated tumor size — is what determines the pathologic tumor stage (pT). This distinction is important: a large encapsulated tumor with a small invasive component may still be staged as pT1. Your report will state both the overall tumor size and, when applicable, the size of the invasive component separately.

Lymphovascular invasion

When an invasive component is present, the pathologist will assess whether cancer cells have entered small blood vessels or lymphatic channels near the tumor — a finding called lymphovascular invasion. Its presence indicates that cancer cells have a potential route to travel to nearby lymph nodes or, through the bloodstream, to distant organs. Lymphovascular invasion is uncommon in encapsulated papillary carcinoma but is reported when seen. Your report will state whether it is “present” or “absent.”

Surgical margins

A margin is the edge of tissue removed during surgery. The pathologist examines the cut surfaces to determine whether cancer cells are present at the edge.

• Negative (clear) margin — No cancer cells at the cut edge. This suggests the tumor was completely removed.
• Positive margin — Cancer cells are visible at the cut edge, indicating the tumor extends beyond what was removed. Additional surgery or radiation therapy is typically recommended.

A wider negative margin generally reduces the risk of local recurrence. For non-invasive EPC, the margin principles are similar to those for DCIS — a minimum of 2 mm of normal tissue between the tumor and the cut edge is generally considered adequate for lumpectomy. When an invasive component is present, margin assessment follows the same standards as for invasive ductal carcinoma.

Lymph nodes

For non-invasive encapsulated papillary carcinoma, lymph node spread does not occur, and lymph nodes are not routinely removed. When an invasive component is present, a sentinel lymph node biopsy is typically performed to check whether cancer has spread to the axillary (underarm) lymph nodes. Lymph node spread in invasive encapsulated papillary carcinoma is uncommon but can occur. Your report will state the number of lymph nodes examined and whether any contain cancer cells.

Biomarker and molecular testing

Biomarker testing is performed on encapsulated papillary carcinoma to help guide treatment decisions, particularly when an invasive component is present.

Estrogen receptor (ER) and progesterone receptor (PR)

The large majority of encapsulated papillary carcinomas are hormone receptor-positive — they express estrogen receptor (ER) and/or progesterone receptor (PR). Testing is performed by immunohistochemistry (IHC), and results are reported as a percentage of positive cells (e.g., “95% ER-positive”), as staining intensity (weak, moderate, or strong), and, optionally, as an Allred or H-score.

Hormone receptor-positive encapsulated papillary carcinoma may benefit from adjuvant endocrine (hormone-blocking) therapy — typically tamoxifen or an aromatase inhibitor — particularly when an invasive component is present or when associated DCIS is hormone receptor-positive. Your oncologist will advise whether endocrine therapy is appropriate for your situation.

HER2

Most encapsulated papillary carcinomas are HER2-negative. When tested, HER2 status uses the same IHC scoring system (0, 1+, 2+, 3+) as for other breast cancers, with equivocal 2+ results confirmed by fluorescence in situ hybridization (FISH). Tumors scoring 1+ or 2+/FISH-negative are classified as HER2-low; those scoring 3+ are HER2-positive. In the rare cases where encapsulated papillary carcinoma with invasion is HER2-positive, treatment is approached in the same way as HER2-positive invasive ductal carcinoma.

Genomic testing

For patients with hormone receptor-positive, HER2-negative encapsulated papillary carcinoma with an invasive component, genomic tests such as the 21-gene recurrence score (Oncotype DX) may occasionally be considered to estimate recurrence risk and guide chemotherapy decisions. Because the invasive component of EPC is typically low-grade and hormone receptor-positive, recurrence scores are often low, consistent with a good prognosis and the likelihood that hormone therapy alone is sufficient. Your oncologist will discuss whether genomic testing is relevant to your case.

For more information about breast cancer biomarkers, visit our Biomarkers and Molecular Testing section.

Treatment effect and residual cancer burden

For patients with invasive encapsulated papillary carcinoma who receive chemotherapy or hormone therapy before surgery (neoadjuvant therapy), the pathology report will describe how much tumor remains after treatment. The Residual Cancer Burden (RCB) index measures the size of the residual tumor bed, the percentage of remaining cancer cells, and the extent of lymph node involvement. It is used to classify the degree of response:

• RCB-0 — No residual invasive cancer (pathologic complete response). Most favorable outcome.
• RCB-I — Minimal residual disease.
• RCB-II — Moderate residual disease.
• RCB-III — Extensive residual disease; higher risk of recurrence.

Neoadjuvant therapy is uncommonly used for encapsulated papillary carcinoma without invasion, given its generally low-risk biology. It may be considered for larger or higher-grade invasive cases.

Pathologic stage (pTNM)

The pathologic stage of encapsulated papillary carcinoma uses the standard TNM staging system for breast cancer.

Tumor stage (pT)

Non-invasive encapsulated papillary carcinoma — in which the tumor cells remain within the capsule — is staged as pTis (carcinoma in situ), regardless of the tumor’s overall size. When an invasive component is present, staging is based on the size of the invasive component only:

• pTis — No invasion; tumor confined within the capsule.
• pT1mi — Invasive component 1 mm or smaller.
• pT1a — Invasive component larger than 1 mm but 5 mm or smaller.
• pT1b — Invasive component larger than 5 mm but 10 mm or smaller.
• pT1c — Invasive component larger than 10 mm but 20 mm or smaller.
• pT2 — Invasive component larger than 20 mm but 50 mm or smaller.
• pT3 — Invasive component larger than 50 mm.
• pT4 — Tumor has grown into the chest wall or skin.

Nodal stage (pN)

Nodal staging applies only when an invasive component is present, and lymph nodes have been removed and examined:

• pN0 — No cancer in any lymph nodes examined.
• pN0(i+) — Isolated tumor cells only (≤0.2 mm) — not counted as positive.
• pN1mi — Micrometastases only (0.2–2 mm).
• pN1a — Cancer in 1–3 axillary lymph nodes, at least one deposit larger than 2 mm.
• pN2a — Cancer in 4–9 axillary lymph nodes.
• pN3a — Cancer in 10 or more axillary lymph nodes.

What is the prognosis for encapsulated papillary carcinoma?

The prognosis for encapsulated papillary carcinoma is excellent — it is among the most favorable of all breast cancer diagnoses.

For non-invasive encapsulated papillary carcinoma (no invasion, intact capsule), the tumor behaves like DCIS. Most patients are cured by complete surgical removal with clear margins. The risk of local recurrence is very low, and spread to lymph nodes or distant organs is essentially nonexistent. Radiation therapy after lumpectomy may further reduce the risk of local recurrence, as it does in DCIS.

When associated DCIS is also present in the surrounding breast tissue, its extent and grade influence surgical planning and the decision about radiation therapy, similar to DCIS managed on its own.

For encapsulated papillary carcinoma with invasion, prognosis depends on the features of the invasive component: its size, grade, lymph node status, margin status, and biomarker profile (ER/PR/HER2). Even in the presence of a small invasive component, the overall outlook remains favorable compared to conventional invasive ductal carcinoma, because invasive EPC tends to be low grade and hormone receptor-positive. However, treatment decisions — including the role of radiation, endocrine therapy, and occasionally chemotherapy — are made based on the invasive component’s characteristics, following the same principles as for invasive ductal carcinoma of equivalent stage.

Questions to ask your doctor

Your pathology report contains important information that will guide your care. The following questions may help you prepare for your next appointment.

• Is my encapsulated papillary carcinoma non-invasive, or is an invasive component present?
• If invasion is present, how large is the invasive component, and what is its grade?
• What is the nuclear grade of the encapsulated papillary carcinoma itself?
• Was DCIS found in the surrounding breast tissue, and how extensive is it?
• Were the surgical margins clear? Is the margin distance adequate?
• Were any lymph nodes removed and examined, and were any positive?
• Was lymphovascular invasion seen?
• What were the hormone receptor (ER and PR) results, and how do they affect my treatment?
• What is the HER2 status — negative, low, or positive?
• Would I benefit from radiation therapy after surgery?
• Is endocrine (hormone-blocking) therapy recommended, and for how long?
• Is genomic testing (such as Oncotype DX) relevant for my case?
• What follow-up imaging and appointments will I need?